TRACON Pharma Reports Second Quarter Financial Results And Provides Corporate Update
SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 and Recent Corporate Highlights
In July, TRACON and its partner, Santen Pharmaceutical Co. Ltd. (Santen), announced the initiation of a Phase 2a study of DE-122, the ophthalmic formulation of TRC105, for the treatment of patients with wet age-related macular degeneration (AMD).
Second Quarter 2017 and Recent Corporate Highlights
In July, TRACON and its partner, Santen Pharmaceutical Co. Ltd. (Santen), announced the initiation of a Phase 2a study of DE-122, the ophthalmic formulation of TRC105, for the treatment of patients with wet age-related macular degeneration (AMD).